CSIMarket Company Name, Ticker, Suppliers, else..
 
Theseus Pharmaceuticals Inc   (THRX)
Other Ticker:  
 
 
Price: $4.0600 $0.00 0.000%
Day's High: $4.07 Week Perf: -0.49 %
Day's Low: $ 4.06 30 Day Perf: 0.74 %
Volume (M): 3,123 52 Wk High: $ 4.20
Volume (M$): $ 12,680 52 Wk Avg: $3.47
Open: $4.06 52 Wk Low: $2.05



 Market Capitalization (Millions $) 178
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -198
 Capital Exp. (TTM) (Millions $) 1

Theseus Pharmaceuticals Inc
Theseus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, USA. It specializes in developing innovative immunotherapy treatments for cancer patients. Founded in 2016, the company is led by an experienced management team, including Dr. John C. Reed, MD, PhD, as the CEO and Dr. Frank Nestle, MD, PhD, as the Chief Scientific Officer.

Theseus Pharmaceuticalse pipeline focuses on immune cell therapies that target solid tumors. Its lead product candidate, ThNK-1, is a CAR-T (Chimeric Antigen Receptor T-cell) therapy that targets the protein CD73, which is highly expressed in various cancer cells. ThNK-1 is in Phase 1 clinical trials for the treatment of advanced solid tumors.

The company also has several other preclinical programs in development, including TNK-2, a dual-targeting CAR-T therapy for the treatment of solid tumors, and TNK-3, a TCR (T-cell receptor) therapy for targeting solid tumors with neoantigens.

Theseus Pharmaceuticals has received significant funding from reputable sources. It has raised more than $120 million in various rounds of financing from investors, including Canaan Partners, 6 Dimensions Capital, Morningside Ventures, and Parian Global Management.

The company collaborates with prominent research institutions and biopharmaceutical companies to advance its technologies. Theseus has strategic partnerships with the University of British Columbia and Novartis for the development and commercialization of its CAR-T and TCR therapies.

Overall, Theseus Pharmaceuticals is a promising biotechnology company that aims to improve cancer treatment options through innovative immunotherapies. Its strong management team, well-funded pipeline, and strategic partnerships are likely to continue to drive its growth in the coming years.


   Company Address: 314 Main Street Cambridge 2142 MA
   Company Phone Number: 400-9491   Stock Exchange / Ticker: NASDAQ THRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals Inc Releases Impressive Financial Third Quarter Earnings, Solidifying Its Position in the Major Pharmaceutical Preparations Market



During the past 5 trading days, Theseus Pharmaceuticals Inc stock saw a significant surge of 53.49%. However, the overall performance of the stock reflects a downward trend, with a year-to-date decline of -36.66%. Further analysis indicates that the stock is currently trading -52.2% below its 52-week average on NASDAQ. The recent financial results of Theseus Pharmaceuticals Inc shed light on the company's top-line expectations and operating loss, leaving investors curious about the future.
Top-line Expectations and Operating Loss:
The stockholders were not anticipating any improvements in the top-line during the earnings cycle of fiscal July to September 30, 2023. However, investors were closely monitoring the company's operating loss, which amounted to $-16.403 million during this period. This represents a deterioration compared to the third quarter of 2022, which recorded an operating loss of $-15.948 million. The increase in operating loss raises concerns about Theseus Pharmaceuticals Inc's ability to generate revenue.
Theseus Pharmaceuticals Inc

Financial Crisis Looms Over Theseus Pharmaceuticals Inc as Operating Deficit Skyrockets



Despite shareholders not anticipating any positive changes in the top-line performance of Theseus Pharmaceuticals Inc (THRX) during the April to June 2023 reporting cycle, recent financial reports have revealed a significant operating deficit of $-17.587 million. However, there is a glimmer of hope as the company's CEO actively seeks new financial plans to ensure the emergence of additional revenue sources. This article examines the impact of THRX's current financial situation and highlights the company's efforts to overcome challenges.
Understanding the Current Situation:
During the specified period, THRX has experienced a widening operating deficit, reaching $-14.805 million, compared to the $-11.649 million deficit reported in Q2 of 2022. These concerning figures have left shareholders worried about the company's ability to sustain its operations and drive profitability. However, it is important to note that these financial reports only provide a snapshot of THRX's current situation and do not account for potential future growth opportunities.
Theseus Pharmaceuticals Inc

Rapid Expansion in Research and Development Puts Theseus Pharmaceuticals Inc in the Spotlight

Theseus Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other life-threatening diseases. The company's main goal is to revolutionize cancer treatment by producing innovative therapies that will improve patients' quality of life.
The company has been on a growth trajectory since its inception and has been making significant strides in its research and development activities. Theseus Pharmaceuticals has made a name for itself in the industry by focusing on developing therapies that target specific types of cancer, thereby providing more personalized treatment options for patients.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com